As of June 2024, the Swedish market continues to attract attention with its robust performance in various sectors, reflecting broader European economic resilience despite global challenges. This backdrop sets a promising stage for growth-oriented companies in Sweden, particularly those with high insider ownership which often signals strong confidence in the company's future from those who know it best.
Top 10 Growth Companies With High Insider Ownership In Sweden
Overview: Attendo AB (publ) operates in the provision of health and care services across Scandinavia and Finland, with a market capitalization of approximately SEK 6.94 billion.
Operations: The company generates SEK 17.63 billion from its Care and Health Care Services segment.
Insider Ownership: 15%
Earnings Growth Forecast: 21.8% p.a.
Attendo, a Swedish company with significant insider ownership, has demonstrated a robust financial performance with earnings growth of 2468.8% over the past year and is forecasted to grow earnings by 21.8% annually. Despite this, its revenue growth at 6.4% per year is modest compared to high-growth benchmarks but exceeds the Swedish market's average. The company's recent strategic initiatives include share repurchases and exploring acquisitions, reflecting an active management approach to capital allocation and business expansion opportunities. However, its Return on Equity is expected to remain low at 9.3%, and it has an unstable dividend track record which might concern income-focused investors.
Overview: Sectra AB (publ) specializes in medical IT and cybersecurity solutions across Sweden, the United Kingdom, the Netherlands, and other European countries, with a market capitalization of SEK 46.55 billion.
Operations: Sectra's revenue is primarily generated from its Imaging IT Solutions and Secure Communications segments, which respectively brought in SEK 2.55 billion and SEK 367.40 million.
Insider Ownership: 30.3%
Earnings Growth Forecast: 19.3% p.a.
Sectra, a Swedish firm with substantial insider ownership, reported strong earnings growth of 14.2% over the past year and forecasts a 19.3% annual increase in earnings, outpacing the Swedish market's average. Its recent product launches, including a diagnostic IT module for genomics and FDA-approved digital pathology solutions, underscore its commitment to innovation in medical imaging and diagnostics. However, its revenue growth forecast of 14.7% annually trails behind higher industry benchmarks but still exceeds general market performance in Sweden.
Overview: Vimian Group AB operates globally in the animal health sector and has a market capitalization of approximately SEK 17.82 billion.
Operations: Vimian Group's revenue is generated from several key segments: Medtech (€109.03 million), Diagnostics (€21.14 million), Specialty Pharma (€153.26 million), and Veterinary Services (€51.63 million).
Insider Ownership: 11%
Earnings Growth Forecast: 58.6% p.a.
Vimian Group, recently profitable, is trading 34.1% below its fair value estimate, signaling potential undervaluation. The company's earnings are expected to increase by a very large margin annually over the next three years, outperforming the Swedish market forecast. Although insider buying has occurred in the past three months, it wasn't substantial. Challenges include low forecasted Return on Equity and significant one-off items impacting earnings quality. Recent leadership changes could influence future strategy and performance.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include OM:ATTOM:SECT B and
